Thyroid Cancer
Conditions
Keywords
apatinib, Iodine-131, Differentiated Thyroid Cancer, refractory, resistant
Brief summary
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer
Interventions
DRUGApatinib
Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hurthle cells, poorly differentiated carcinoma). At least one measurable lesion (helical CT scan long diameter ≥10mm, meet the requirements of the standard Response Evaluation Criteria In Solid Tumors（RESCIST） version 1.1); 2. Disease progression within 14 months before inclusion; 3. Subjects must be 131I-refractory / resistant as defined by at least one of the following; * Lesions that do not demonstrate iodine uptake on any radioiodine scan * Subjects received a single radioactive iodine therapy within 12 months (≥ 3.7 Giga Becquerel (GBq) \[≥ 100 millicurie (mCi) \]) and target lesion disease progression * Every two radioactive iodine treatment interval \<12 months, doses ≥ 3.7 GBq \[≥100 mCi\], disease progress more than 12 months after at least once iodine therapy; * Received a total dose of radioactive iodine therapy ≥ 22.2 GBq (≥ 600 mCi) 4. main organs function is normal; 5. Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :0-2; 6. An expected survival of ≥ 3 months; 7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug; 8. Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
Exclusion criteria
1. Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or sarcoma); 2. Received VEGFR inhibitor treatment within 1 month; 3. Subjects with poor-controlled arterial hypertension (systolic blood pressure\> 140 mmHg and diastolic blood pressure \> 90 mm Hg) despite standard medical management; Coronary heart disease greater than ClassII; II-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class II cardiac dysfunction; 4. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction); 5. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 3 months; 6. Abnormal Coagulation (INR\>1.5、APTT\>1.5 UNL), with tendency of bleed; 7. Received anti-thyroid cancer chemotherapy treatment (allows the use of low-dose chemotherapy with radiation sensitizer) or thalidomide(or derivative) therapy; 8. Pregnant or lactating women; 9. Other conditions regimented at investigators' discretion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) | An expected average of 8 weeks | Disease control rate |
| Objective response rate (ORR) | An expected average of 8 weeks | Objective response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | Up to approximately 43 months | progression free survival |
| Overall survival (OS) | Up to approximately 48 months | overall survival |
Countries
China
Outcome results
None listed